loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Dornase Alfa reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Dornase Alfa

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Pulmozyme

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 774

    2018 Revenue in Millions : 761

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 715

    2019 Revenue in Millions : 837

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 609

    2020 Revenue in Millions : 681

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 594

    2021 Revenue in Millions : 609

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 524

    2022 Revenue in Millions : 594

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Disease

    Currency : USD

    2014 Revenue in Millions : 4.40%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Disease

    Currency : USD

    2015 Revenue in Millions : 603

    2014 Revenue in Millions : 659

    Growth (%) : 9%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2016 Revenue in Millions : 678

    2015 Revenue in Millions : 645

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2017 Revenue in Millions : 774

    2016 Revenue in Millions : 726

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Pulmozyme

    Dornase Alfa

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Pulmozyme

    Switzerland
    arrow
    Luxepack
    Not Confirmed

    Roche

    Dornase Alfa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2018 Revenue in Millions : 746

    2017 Revenue in Millions : 737

    Growth (%) : 1%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF